###begin article-title 0
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 69 77 <span type="species:ncbi:9606">Patients</span>
Five Novel Mutations in Steroidogenic Factor 1 (SF1, NR5A1) in 46,XY Patients With Severe Underandrogenization But Without Adrenal Insufficiency
###end article-title 0
###begin p 1
Birgit Kohler and Lin Lin contributed equally to this work.
###end p 1
###begin p 2
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 556 561 556 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 177 182 <span type="species:ncbi:9606">Human</span>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
###xml 415 423 <span type="species:ncbi:9606">patients</span>
###xml 581 589 <span type="species:ncbi:9606">patients</span>
###xml 744 752 <span type="species:ncbi:9606">patients</span>
###xml 913 921 <span type="species:ncbi:9606">patients</span>
###xml 1009 1016 <span type="species:ncbi:9606">patient</span>
###xml 1059 1066 <span type="species:ncbi:9606">patient</span>
###xml 1177 1184 <span type="species:ncbi:9606">patient</span>
###xml 1576 1584 <span type="species:ncbi:9606">patients</span>
###xml 1654 1660 <span type="species:ncbi:9606">humans</span>
Steroidogenic factor 1 (SF1, NR5A1) is a nuclear receptor that regulates multiple genes involved in adrenal and gonadal development, steroidogenesis, and the reproductive axis. Human mutations in SF1 were initially found in two 46,XY female patients with severe gonadal dysgenesis and primary adrenal failure. However, more recent case reports have suggested that heterozygous mutations in SF1 may also be found in patients with 46,XY partial gonadal dysgenesis and underandrogenization but normal adrenal function. We have analyzed the gene encoding SF1 (NR5A1) in a cohort of 27 patients with 46,XY disorders of sex development (DSD) from the German network of DSD. Heterozygous SF1 mutations were found in 5 out of 27 (18.5%) of cases. Four patients with SF1 mutations presented with the similar phenotype of mild gonadal dysgenesis, severe underandrogenization, and absent Mullerian structures. Of these, two patients harbored missense mutations within the DNA-binding region of SF1 (p.C33S, p.R84H), one patient had a nonsense mutation (p.Y138X) and one patient had a frameshift mutation (c.1277dupT) predicted to disrupt RNA stability or protein function. One additional patient ([c.424_427dupCCCA]+[p.G146A]) displayed a more marked phenotype of severe gonadal dysgenesis, normal female external genitalia, and Mullerian structures. Functional studies of the missense mutants (p.C33S, p.R84H) and of one nonsense mutant (p.Y138X) revealed impaired transcriptional activation of SF1-responsive target genes. To date, adrenal insufficiency has not occurred in any of the patients. Thus, SF1 mutations are a relatively frequent cause of 46,XY DSD in humans.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 209 226 209 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R15">Lala et al., 1992</xref>
###xml 384 403 384 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R22">Parker et al., 2002</xref>
Steroidogenic factor-1 (SF1/Ad4BP, NR5A1; MIM# 184757) is a nuclear receptor that was first identified following the search for a common regulator of the cytochrome P450 steroid hydroxylase family of enzymes [Lala et al., 1992]. Subsequent studies have revealed that SF1 regulates a great number of genes involved in gonadal and adrenal development, reproduction and steroidogenesis [Parker et al., 2002].
###end p 4
###begin p 5
###xml 366 391 366 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R21">Parker and Schimmer, 1997</xref>
###xml 487 507 487 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R14">Krylova et al., 2005</xref>
SF1 is believed to bind to the response elements of target genes as a monomer. Critical regions of SF1 involved in transcriptional regulation include a two zinc finger DNA-binding domain (DBD), an "A" box region found in monomeric nuclear receptors, a hinge region, and a helical ligand-binding domain (LBD) region containing an activation function-2 (AF-2) domain [Parker and Schimmer, 1997]. Crystalization of the LBD of SF1 has revealed that phospholipids may act as ligands for SF1 [Krylova et al., 2005].
###end p 5
###begin p 6
###xml 254 273 254 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R10">Hatano et al., 1994</xref>
###xml 275 296 275 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R11">Ingraham et al., 1994</xref>
###xml 298 317 298 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R8">Hanley et al., 1999</xref>
###xml 348 353 348 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ftzf1</italic>
###xml 506 522 506 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R18">Luo et al., 1994</xref>
###xml 524 543 524 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R19">Majdic et al., 2002</xref>
###xml 666 684 666 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R6">Bland et al., 2000</xref>
###xml 72 76 <span type="species:ncbi:10090">mice</span>
###xml 81 87 <span type="species:ncbi:9606">humans</span>
###xml 358 362 <span type="species:ncbi:10090">mice</span>
SF1 is essential for gonadal and adrenal differentiation in mammals. In mice and humans, SF1 is expressed very early in the urogenital ridge and continues to be highly expressed in the developing adrenal, gonad, ventromedial hypothalamus, and pituitary [Hatano et al., 1994; Ingraham et al., 1994; Hanley et al., 1999]. Targeted disruption of Sf1 (Ftzf1) in mice results in gonadal and adrenal agenesis, persistence of Mullerian structures and abnormalities of the hypothalamus and pituitary gonadotropes [Luo et al., 1994; Majdic et al., 2002]. Heterozygous animals have a milder phenotype including an impaired adrenal stress response and reduced testicular size [Bland et al., 2000].
###end p 6
###begin p 7
###xml 188 193 188 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R1">&#8203;1999</xref>
###xml 195 200 195 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R2">&#8203;2002</xref>
###xml 416 438 416 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R1">Achermann et al., 1999</xref>
###xml 442 458 442 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R12">Ito et al., 2000</xref>
###xml 603 625 603 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R2">Achermann et al., 2002</xref>
###xml 769 801 769 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R4">Biason-Lauber and Schoenle, 2000</xref>
###xml 3 9 <span type="species:ncbi:9606">humans</span>
###xml 49 57 <span type="species:ncbi:9606">patients</span>
In humans, SF1 mutations were first described in patients with 46,XY disorders of sex development (DSD), Mullerian structures, and primary adrenal failure (MIM# 184757) [Achermann et al., ​1999, ​2002]. The first of these mutations (p.G35E) was a de novo heterozygous change affecting a critical amino acid in the "P" box region of the first zinc-finger of the DNA binding domain that severely affects SF1 function [Achermann et al., 1999​;​ Ito et al., 2000]. The second mutation was a recessively-inherited homozygous change (p.R92Q) affecting the "A" box of SF1 and causing partial loss of function [Achermann et al., 2002]. A heterozygous SF1 mutation has also been reported in a 46,XX female with primary adrenal failure and apparently normal ovarian development [Biason-Lauber and Schoenle, 2000].
###end p 7
###begin p 8
###xml 157 176 157 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R7">Correa et al., 2004</xref>
###xml 178 197 178 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R20">Mallet et al., 2004</xref>
###xml 199 220 199 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R9">Hasegawa et al., 2004</xref>
###xml 222 238 222 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R17">Lin et al., 2007</xref>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 478 486 <span type="species:ncbi:9606">patients</span>
###xml 653 661 <span type="species:ncbi:9606">patients</span>
Recently, heterozygous SF1 mutations have been described in seven 46,XY patients with ambiguous genitalia, gonadal dysgenesis, but no adrenal insufficiency [Correa et al., 2004; Mallet et al., 2004; Hasegawa et al., 2004; Lin et al., 2007]. The potential dosage-dependent actions of SF1 suggest that these heterozygous SF1 changes might lead to a partial phenotype of 46,XY DSD with normal adrenal function. Here, we report five novel SF1 mutations identified in a cohort of 27 patients with severe underandrogenization and variable degrees of gonadal dysgenesis. These results suggest that heterozygous SF1 changes are a relatively frequent finding in patients with 46,XY gonadal dysgenesis/DSD.
###end p 8
###begin title 9
MATERIALS AND METHODS
###end title 9
###begin title 10
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 10
###begin p 11
###xml 41 49 <span type="species:ncbi:9606">patients</span>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
###xml 321 329 <span type="species:ncbi:9606">patients</span>
###xml 533 541 <span type="species:ncbi:9606">patients</span>
The cohort studied consisted of 27 46,XY patients from the "German Network of Disorders of Sex Development." The patients had presented with phenotypes ranging from ambiguous genitalia to normal female genitalia and had been diagnosed with variable degrees of gonadal dysgenesis. Mullerian structures were reported in 17 patients. Adrenal insufficiency was not present in any of them. Dysmorphic or systemic features (e.g., kidney, heart, limbs) were absent. Informed consent for the genetic studies was obtained from all parents or patients according to institutional guidelines.
###end p 11
###begin title 12
Molecular Analysis of NR5A1
###end title 12
###begin p 13
###xml 99 104 99 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
Genomic DNA was extracted from peripheral blood leukocytes and exons 2-7 of the gene encoding SF1 (NR5A1) were PCR-amplified (primer sequences available on request). PCR products were purified using exonuclease 1 and shrimp alkaline phosphatase (New England Biolabs, Cambridge, UK; USB, Cleveland, OH) and sequenced using a V3 kit and 3130x analyzer (Applied Biosystems, Foster City, CA). DNA mutation numbering is based on GenBank reference DNA sequence NM_004959.3, with the A of the ATG initiation codon designated 11 ().
###end p 13
###begin title 14
Electromobility Shift Assays
###end title 14
###begin p 15
###xml 239 245 239 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cyp11a</italic>
###xml 282 284 282 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 385 401 385 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R12">Ito et al., 2000</xref>
Wild-type (WT) and mutant SF1 proteins were in-vitro translated from the pCMX expression vector using the TNT reticulocyte system (Promega, Southampton, UK). Synthetic oligonucleotide probes corresponding to the 3' SF1 binding site on the Cyp11a minimal promoter were labeled with [32P]dCTP by Klenow polymerase and electromobility shift assays were performed as described previously [Ito et al., 2000].
###end p 15
###begin title 16
Studies of SF1 Expression and Nuclear Localization
###end title 16
###begin p 17
###xml 378 383 <span type="species:ncbi:9606">human</span>
Mutant green fluorescent protein (GFP)-SF1 constructs were generated by site-directed mutagenesis in a pAcGFP-C1 vector (Clontech, Oxford, UK) to produce mutant fusion proteins with a GFP tag at the amino-terminus of SF1. Studies of protein expression and cellular localization were performed by transfecting WT and mutant pAcGFP-C1SF1 expression vectors (0.8 mug) into tsa 201 human embryonic kidney cells. After 24 hr, cells were fixed and nuclear counterstaining performed with Vectashield containing DAPI (Vector Laboratories, Peterborough, UK).
###end p 17
###begin title 18
Transient Gene Expression Assays
###end title 18
###begin p 19
###xml 639 645 639 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cyp11a</italic>
###xml 790 806 787 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R17">Lin et al., 2007</xref>
###xml 880 886 877 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cyp11a</italic>
###xml 891 894 888 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIS</italic>
###xml 1132 1139 1129 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 915 920 <span type="species:ncbi:10090">mouse</span>
###xml 938 943 <span type="species:ncbi:10090">mouse</span>
Expression vectors containing the p.C33S and p.R84H missense mutants and p.Y138X nonsense mutant were generated by site-directed mutagenesis (QuikChange, Stratagene, Amsterdam, The Netherlands) using WT pCMXSF1 as a template. Transient transfection studies were performed in 96-well plates using Lipofectamine 2000 (Invitrogen, Paisley, UK) and a Dual-Luciferase reporter assay system (Promega). Initial studies were performed in tsa 201 cells by transfecting empty, WT, or mutant SF1 expression vectors (2 ng/well) (p.G35E, p.C33S, p.R84H, p.Y138X) with SF1-responsive minimal promoters linked to luciferase (100 ng/well) (data shown for Cyp11a). In addition, synergistic activation of the LHbeta promoter by SF1 and Egr1 (2 ng/well) was studied in tsa 201 cells, as described previously [Lin et al., 2007]. Finally, WT or mutant SF1 vectors (10 ng/well) were cotransfected with Cyp11a and MIS reporters into TM3 (mouse Leydig) and TM4 (mouse Sertoli) cells, respectively. Cells were lysed for 24 hr following transfection and assayed for luciferase activity (FLUOstar Optima; BMG Labtech, Aylesbury, UK), with standardization for Renilla coexpression.
###end p 19
###begin title 20
Studies of Potential Dominant Negative Interactions
###end title 20
###begin p 21
###xml 194 200 194 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cyp11a</italic>
Studies of WT/mutant interactions were performed by transfecting increasing amounts of pCMXWTor mutant SF1 expression vector (0, 1, 2, 5, 10 ng) with either 1 ng empty vector or 1 ng WT SF1 and Cyp11a reporter (100 ng) in tsa 201 cells. Luciferase assays were performed as described above.
###end p 21
###begin title 22
RESULTS
###end title 22
###begin title 23
Cohort Analysis
###end title 23
###begin p 24
###xml 134 141 134 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 146 154 146 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
SF1 mutations were found in 5 out of 27 (18.5%) patients studied. An overview of these changes and clinical phenotypes is provided in Table 1 and Figure 1.
###end p 24
###begin title 25
Case Histories
###end title 25
###begin p 26
###xml 736 743 736 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 624 629 <span type="species:ncbi:9606">human</span>
###xml 674 682 <span type="species:ncbi:9606">Patients</span>
###xml 725 732 <span type="species:ncbi:9606">Patient</span>
###xml 753 761 <span type="species:ncbi:9606">patients</span>
Patients 1-4 were diagnosed with ambiguous genitalia at birth. All these individuals presented with a similar genital phenotype consisting of phallic hypoplasia/clitoromegaly, fusion of the labioscrotal folds, a single perineal opening representing a urogenital sinus, and palpable inguinal gonads. The karyotype was found to be 46,XY in each case, but Mullerian structures (uterus, upper vagina) were absent. Gonadectomy-performed before the age of 2 years-revealed bilateral testes with Wolffian structures (epididymides, vasa deferentia). Endocrine evaluation at diagnosis showed low testosterone levels before and after human chorionic-gonadotropin (hCG) stimulation in Patients 1, 2 and 4, and low basal testosterone in Patient 3 (Table 1). In all patients, female gender assignment was made because of the significant undervirilization and clitoroplasty were undertaken following discussion and with parental consent.
###end p 26
###begin p 27
###xml 332 339 332 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient 5 presented as a young adult with primary amenorrhea. She had normal female external genitalia. Gonadotropins (follicle-stimulating hormone [FSH] 111.9 U/l; luteinizing hormone [LH] 25.8 U/l) were elevated, karyotype was found to be 46,XY, and Mullerian structures and bilateral streak gonads were identified on ultrasound (Table 1).
###end p 27
###begin p 28
###xml 181 188 181 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 87 95 <span type="species:ncbi:9606">Patients</span>
###xml 252 259 <span type="species:ncbi:9606">Patient</span>
Basal cortisol and dehydroepiandrosterone sulfate (DHEAS) were within normal ranges in Patients 1-4 and no symptoms or signs of adrenal insufficiency have emerged during follow-up (Table 1). A synacthen stimulation test performed at 17 years of age in Patient 2 showed a very good cortisol response.
###end p 28
###begin title 29
SF1 (NR5A1) Mutations
###end title 29
###begin p 30
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 62 69 62 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 74 82 74 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 84 92 <span type="species:ncbi:9606">Patients</span>
###xml 148 155 <span type="species:ncbi:9606">Patient</span>
###xml 176 183 <span type="species:ncbi:9606">Patient</span>
###xml 214 221 <span type="species:ncbi:9606">Patient</span>
###xml 282 289 <span type="species:ncbi:9606">Patient</span>
###xml 505 512 <span type="species:ncbi:9606">Patient</span>
###xml 790 797 <span type="species:ncbi:9606">patient</span>
An overview of the SF1 (NR5A1) mutations detected is shown in Table 1 and Figure 1. Patients 1 and 2 harbor heterozygous missense mutations in SF1 (Patient 1: c.98G>C, p.C33S; Patient 2: c.251G>A, p.R84H), whereas Patient 3 has a heterozygous nonsense mutation (c.414C>A, p.Y138X). Patient 4 is heterozygous for a single nucleotide duplication (c.1277dupT), which is predicted to result in a frameshift and disruption of the ligand binding domain of SF1. Her mother also carries this heterozygous change. Patient 5 has a 4 base pair duplication (c.424_427dupCCCA) in exon 4 in one allele, which is predicted to result in a frameshift and premature stop codon after seven amino acids. A c.437G>C polymorphism (p.G146A) was present on the second allele, which was confirmed by subcloning the patient's DNA. Analysis of DNA from 100 healthy control subjects did not detect any of these key novel changes by restriction analysis (data not shown). The p.G146A change is a recognized nonsynonymous polymorphism in SF1 (rs1110061).
###end p 30
###begin title 31
Electromobility Shift Assays
###end title 31
###begin p 32
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cyp11a</italic>
###xml 219 226 219 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2A</xref>
Studies of the 3' Cyp11a promoter showed absent binding for the p.C33S mutant consistent with its position within the "P" box of the DBD. The p.R84H mutant and the p.Y138X truncated protein both showed reduced binding (Fig. 2A).
###end p 32
###begin title 33
SF1 Expression and Cellular Localization
###end title 33
###begin p 34
###xml 320 327 320 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2B</xref>
GFP-tagged WT SF1 showed strong nuclear localization with nucleolar exclusion. A similar pattern was seen with the p.R84H mutant vector. The p.C33S construct showed marked subnuclear focal aggregation in many cells, whereas the p.Y138X nonsense mutant appeared to be located in a diffuse pattern throughout the nucleus (Fig. 2B).
###end p 34
###begin title 35
Functional Studies of SF1 Activity
###end title 35
###begin p 36
###xml 97 106 97 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3A-D</xref>
###xml 246 253 246 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3E</xref>
###xml 367 387 367 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R26">WuQiang et al., 2003</xref>
All mutants studied (p.C33S, p.R84H, p.Y138X) showed markedly impaired transcriptional activity (Fig. 3A-D). Cotransfection of mutant with WT SF1 did not show a dominant negative effect even when 10:1 ratios of mutant:WT vector were transfected (Fig. 3E). The p.G146A polymorphism in SF1 has been shown previously to be associated with approximately 80% WT activity [WuQiang et al., 2003].
###end p 36
###begin title 37
DISCUSSION
###end title 37
###begin p 38
###xml 221 226 221 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
###xml 351 358 351 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 250 256 <span type="species:ncbi:9606">humans</span>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
Here, we present five novel heterozygous SF1 mutations in a cohort of 27 46,XY patients (18.5%) with severe underandrogenization but without adrenal insufficiency. These findings substantially increase the number of SF1 (NR5A1) mutations reported in humans, and show that mutations in SF1 can be found in patients with a range of phenotypic features (Table 2).
###end p 38
###begin p 39
###xml 24 32 <span type="species:ncbi:9606">patients</span>
###xml 650 658 <span type="species:ncbi:9606">Patients</span>
Within our series, four patients (heterozygous p.C33S, p.R84H, p.Y138X, and c.1277 dupT) presented with a similar phenotype consisting of severe underandrogenization of the external genitalia, bilateral testes, and Wolffian structures, but absence of Mullerian structures (uterus, fallopian tubes). These findings suggest that androgen biosynthesis and action were compromised during early fetal development (9-16 weeks), but that sufficient secretion of anti-Mullerian hormone (AMH) occurred from Sertoli cells to allow regression of Mullerian structures during this critical developmental period. The presence of well-formed Wolffian structures in Patients 1-4 is unusual given the degree of underandrogenization observed. Whether the development of Wolffian structures with relatively impaired androgenization of the external genitalia will be a feature that distinguishes SF1 mutations from other diagnoses, such as partial gonadal dysgenesis or partial androgen insensitivity, remains to be seen.
###end p 39
###begin p 40
###xml 377 383 377 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 460 467 460 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2A</xref>
###xml 552 561 552 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3A-E</xref>
###xml 616 623 616 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2B</xref>
###xml 824 844 824 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R3">Baumann et al., 2001</xref>
###xml 846 866 846 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R23">Vottero et al., 2002</xref>
###xml 868 886 868 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R5">Black et al., 2004</xref>
###xml 1010 1016 1010 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 809 814 <span type="species:ncbi:9606">human</span>
The identification of naturally-occurring missense mutations in SF1 is also helping to reveal important functional domains for nuclear receptor action. The amino acids of the missense mutations (p.C33S, p.R84H) are highly conserved in different species. The mutated cysteine (p.C33S) plays a central role in formation of the first zinc finger of the DNA binding domain of SF1 (Fig. 1). The C33S change results in impaired DNA binding to SF1 response elements (Fig. 2A), a complete loss of transcriptional activation without dominant negative activity (Fig. 3A-E) and abnormal clustering in sub-nuclear aggregations (Fig. 2B). These foci likely represent promyelocytic leukemia (PML) or nuclear domain 10 (ND10) bodies, and have been reported previously with several nuclear receptor mutations associated with human disease [Baumann et al., 2001; Vottero et al., 2002; Black et al., 2004]. The arginine at position 84 lies between the zinc-fingers and "A"-box of SF1 in the carboxylterminal DNA-binding region (Fig. 1). This change also disrupts DNA binding and transcriptional activation, with little effect on cellular localization. Finally, the nonsense mutation (p.Y138X) results in a truncated protein with loss of the LBD, and the frameshift mutation resulting from the duplication c.1277dupT is predicted to lead to abnormal protein sequence. However, it is feasible that RNA containing the Y138X change is subject to nonsense-mediated decay.
###end p 40
###begin p 41
###xml 609 629 609 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R26">WuQiang et al., 2003</xref>
###xml 644 649 644 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R24">&#8203;2005</xref>
###xml 651 656 651 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R25">&#8203;2006</xref>
###xml 40 47 <span type="species:ncbi:9606">Patient</span>
###xml 407 414 <span type="species:ncbi:9606">Patient</span>
###xml 891 898 <span type="species:ncbi:9606">patient</span>
Compared to the first four individuals, Patient 5 has a more severe phenotype, as she has normal female external genitalia and presented only in adolescence with absent breast development and primary amenorrhea. A uterus and streak gonads were found. The mutation c.424_427dupCCCA results in a frameshift and premature stop codon after seven amino acids. In addition to this heterozygous frameshift change, Patient 5 also harbors a heterozygous p.G146A polymorphism on the other allele. This p.G146A is reported to have approximately 80% of WT function and to be associated with micropenis or cryptorchidism [WuQiang et al., 2003; Wada et al., ​2005, ​2006]. Thus, we hypothesize that combination of the hypomorphic polymorphism, together with the heterozygous frameshift mutation, reduces gene dosage of SF1 below haploinsufficiency, resulting in the more severe phenotype observed in this patient.
###end p 41
###begin p 42
###xml 126 145 126 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R8">Hanley et al., 1999</xref>
###xml 147 179 147 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R4">Biason-Lauber and Schoenle, 2000</xref>
###xml 263 270 <span type="species:ncbi:9606">Patient</span>
While SF1 has a key role in testis development and function, the effects of reduced SF1 activity in the ovary are less clear [Hanley et al., 1999; Biason-Lauber and Schoenle, 2000]. The identification of a heterozygous frameshift mutation in SF1 in the mother of Patient 4 provides evidence that heterozygous SF1 mutations may be inherited in a sex-limited dominant fashion. Mothers may carry such changes, but have preserved ovarian function, whereas 46,XY offspring are affected. This finding has important implications for counseling, as heterozygous females may resemble "carriers" in an X-linked disorder.
###end p 42
###begin p 43
###xml 239 252 239 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R13">Jameson, 2004</xref>
###xml 254 270 254 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R16">Lin et al., 2006</xref>
###xml 231 237 <span type="species:ncbi:9606">humans</span>
###xml 287 295 <span type="species:ncbi:9606">patients</span>
Taken together, our findings show that heterozygous SF1 mutations are a relatively frequent finding in individuals with 46,XY DSD, and that the testis may be more sensitive to partial loss of SF1 function than the adrenal gland in humans [Jameson, 2004; Lin et al., 2006]. Whether these patients will develop adrenal insufficiency with time remains to be seen. Thus, determining the genetic cause in 46,XY DSD can have implications for investigation, counseling of families, and long-term follow-up.
###end p 43
###begin title 44
ACKNOWLEDGMENTS
###end title 44
###begin p 45
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 434 439 <span type="species:ncbi:9606">Child</span>
###xml 484 492 <span type="species:ncbi:9606">Children</span>
We are grateful to the patients and families, members of the network, Daniel Kelberman, Ron Evans, Meera Ramayya, J. Larry Jameson, and Masafumi Ito for technical support and vectors. B.K. holds a grant from the Bundesministerium fur Bildung und Forschung (BMBF) Network of Disorders of Sex Development (01GM0311) and J.C.A. holds a Wellcome Trust Senior Research Fellowship in Clinical Science (079666). Research at the Institute of Child Health and Great Ormond Street Hospital for Children National Health Service (NHS) Trust benefits from R&D funding received from the NHS Executive.
###end p 45
###begin p 46
Grant sponsor: Bundesministerium fur Bildung und Forschung (BMBF) Network of Disorders of Sex Development; Grant number: 01GM0311; Grant sponsor: The Wellcome Trust (079666).
###end p 46
###begin title 47
REFERENCES
###end title 47
###begin article-title 48
###xml 101 107 <span type="species:ncbi:9606">humans</span>
A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans
###end article-title 48
###begin article-title 49
Gonadal determination and adrenal development are regulated by the orphan nuclear receptor steroidogenic factor-1, in a dose-dependent manner
###end article-title 49
###begin article-title 50
The glucocorticoid receptor interacting protein 1 (GRIP1) localizes in discrete nuclear foci that associate with ND10 bodies and are enriched in components of the 26S proteasome
###end article-title 50
###begin article-title 51
###xml 59 63 <span type="species:ncbi:9606">girl</span>
Apparently normal ovarian differentiation in a prepubertal girl with transcriptionally inactive steroidogenic factor 1 (NR5A1/SF-1) and adrenocortical insufficiency
###end article-title 51
###begin article-title 52
Transient, ligand-dependent arrest of the androgen receptor in subnuclear foci alters phosphorylation and coactivator interactions
###end article-title 52
###begin article-title 53
###xml 48 52 <span type="species:ncbi:10090">mice</span>
Haploinsufficiency of steroidogenic factor-1 in mice disrupts adrenal development leading to an impaired stress response
###end article-title 53
###begin article-title 54
###xml 48 53 <span type="species:ncbi:9606">human</span>
A microdeletion in the ligand binding domain of human steroidogenic factor 1 causes XY sex reversal without adrenal insufficiency
###end article-title 54
###begin article-title 55
###xml 70 75 <span type="species:ncbi:9606">human</span>
Expression of steroidogenic factor 1 and Wilms' tumour 1 during early human gonadal development and sex determination
###end article-title 55
###begin article-title 56
###xml 63 70 <span type="species:ncbi:9606">patient</span>
Testicular dysgenesis without adrenal insufficiency in a 46,XY patient with a heterozygous inactive mutation of steroidogenic factor-1
###end article-title 56
###begin article-title 57
###xml 140 143 <span type="species:ncbi:10116">rat</span>
Sex-dependent expression of a transcription factor, Ad4BP, regulating steroidogenic P-450 genes in the gonads during prenatal and postnatal rat development
###end article-title 57
###begin article-title 58
The nuclear receptor steroidogenic factor 1 acts at multiple levels of the reproductive axis
###end article-title 58
###begin article-title 59
A naturally occurring steroidogenic factor-1 mutation exhibits differential binding and activation of target genes
###end article-title 59
###begin article-title 60
###xml 3 7 <span type="species:ncbi:10090">mice</span>
###xml 12 15 <span type="species:ncbi:9606">men</span>
Of mice and men: the tale of steroidogenic factor-1
###end article-title 60
###begin article-title 61
Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1
###end article-title 61
###begin article-title 62
###xml 83 88 <span type="species:ncbi:10090">mouse</span>
Steroidogenic factor I, a key regulator of steroidogenic enzyme expression, is the mouse homolog of fushi tarazu-factor I
###end article-title 62
###begin article-title 63
###xml 74 82 <span type="species:ncbi:9606">children</span>
Analysis of DAX1 (NR0B1) and steroidogenic factor-1 (SF1/Ad4BP, NR5A1) in children and adults with primary adrenal failure: ten years' experience
###end article-title 63
###begin article-title 64
Heterozygous missense mutations in steroidogenic factor 1 (SF1/Ad4BP, NR5A1) are associated with 46,XY disorders of sex development with normal adrenal function
###end article-title 64
###begin article-title 65
A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation
###end article-title 65
###begin article-title 66
###xml 9 13 <span type="species:ncbi:10090">mice</span>
Knockout mice lacking steroidogenic factor 1 are a novel genetic model of hypothalamic obesity
###end article-title 66
###begin article-title 67
###xml 61 68 <span type="species:ncbi:9606">patient</span>
Gonadal dysgenesis without adrenal insufficiency in a 46, XY patient heterozygous for the nonsense C16X mutation: a case of SF1 haploinsufficiency
###end article-title 67
###begin article-title 68
Steroidogenic factor 1: a key determinant of endocrine development and function
###end article-title 68
###begin article-title 69
Steroidogenic factor 1: an essential mediator of endocrine development
###end article-title 69
###begin article-title 70
A novel, C-terminal dominant negative mutation of the GR causes familial glucocorticoid resistance through abnormal interactions with p160 steroid receptor coactivators
###end article-title 70
###begin article-title 71
Association of severe micropenis with Gly146Ala polymorphism in the gene for steroidogenic factor-1
###end article-title 71
###begin article-title 72
Association of cryptorchidism with Gly146Ala polymorphism in the gene for steroidogenic factor-1
###end article-title 72
###begin article-title 73
###xml 37 42 <span type="species:ncbi:9606">human</span>
Functional characterization of a new human Ad4BP/SF-1 variation, G146A
###end article-title 73
###begin title 74
Figures and Tables
###end title 74
###begin p 75
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Structure of SF1 including the position of SF1 mutations in 46,XY patients with disorders of sex development. p.G35E and p.R92Q are the first mutations described in SF1 in 46,XY individuals with gonadal dysgenesis and adrenal failure. p.R255L was found in a normal 46,XX female with adrenal failure.The other mutations have been identified in individuals with 46,XY DSD without adrenal insufficiency.The five novel mutations reported here are boxed. DNA RefSeq NM_004959.3.
###end p 75
###begin p 76
###xml 59 60 59 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 203 209 203 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cyp11a</italic>
###xml 357 358 357 358 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
DNA binding, expression, and cellular localization of SF1. A: Electromobility shift assay showing wild-type (WT) and mutant SF1 binding to a labeled probe corresponding to the 3' SF1 binding site of the Cyp11a promoter. In-vitro translated empty vector (-) (lane 1) and an excess of unlabeled cold probe (withWT SF1 protein) (lane 7) were used as controls. B: Cellular localization of GFP-SF1 fusion proteins (green), generated and expressed in tsa 201 cells using a pAcGFP-C1 vector. Nuclear counterstaining was performed with DAPI (blue), and images merged to confirm nuclear localization. WT SF1 showed strong nuclear localization, with relative nucleolar exclusion and very occasional nuclear subfoci. A similar expression and localization pattern to WT was seen for the p.R84H mutant. Clustering in larger subnuclear foci was seen in the cells transfected with the p.C33S mutant.The p.Y138 X mutant showed diffuse nuclear localization.
###end p 76
###begin p 77
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 85 91 85 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cyp11a</italic>
###xml 146 148 146 148 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B:</bold>
###xml 207 209 207 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LH</italic>
###xml 240 243 240 243 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C,D</bold>
###xml 306 312 306 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cyp11a</italic>
###xml 317 320 317 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MIS</italic>
###xml 397 398 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 654 660 654 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cyp11a</italic>
###xml 338 343 <span type="species:ncbi:10090">mouse</span>
###xml 361 366 <span type="species:ncbi:10090">mouse</span>
A: Effect of the SF1 mutants on transcriptional activity of the minimal promoters of Cyp11a in tsa 201 cells as described in the methods section. B: Effect of the SF1mutants on synergistic activation of the LH beta promoter by SF1and Egr1. C,D: Effect of the SF1 mutants on transcriptional activity of the Cyp11a and MIS promoter in TM3 (mouse Leydig) and TM4 (mouse Sertoli) cells, respectively. E: Studies of a potential dominant negative effect of mutant SF1 were performed by transfecting increasing amounts of wild-type (WT) or mutant SF1 (p.C33S, p.R84H, p.Y138X) expression vector (0,1, 2, 5,10 ng) with 1-ng empty vector (-) or 1-ng WT (+) and a Cyp11a promoter reporter (100 ng) in tsa 201 cells. Additional empty vector was transfected to keep DNA quantities consistent. Data represent the mean+/-standard error of the mean (SEM) of three independent experiments, each performed in triplicate.
###end p 77
###begin p 78
###xml 61 62 61 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="TFN1">*</xref>
###xml 53 61 <span type="species:ncbi:9606">Patients</span>
Phenotypes, Genotypes, and Hormonal Data of the Five Patients*
###end p 78
###begin p 79
Normal ranges: basal cortisol, 3-15 mug/dl (<0.5-10 years); DHEAS, <50-352 ng/ml (0.5-7 years), 75-1,312 ng/ml (7-10 years), 150-4,400 ng/ml (>10 years); ACTH, 9-50 pg/ml. Conversion to SI units: testosterone ng/ml x 3.47 for nmol/l; cortisol mug/dl x 27.6 for nmol/l; DHEAS ng/ml x 2.56 for nmol/l; ACTH pg/ml x 0.22 for pmol/l. DNA mutation numbering is based on the GenBank reference DNA sequence NM_004959.3 using current guidelines () and with the A of the ATG initiation codon designated +1.
###end p 79
###begin p 80
Peak cortisol following synacthen stimulation."At birth" refers to the first week of life
###end p 80
###begin p 81
ACTH, adrenocorticotropin; NA, not analyzed.
###end p 81
###begin p 82
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NR5A1</italic>
Molecular and Clinical Features of 46,XY IndividualsWith Mutations in SF1 (NR5A1)
###end p 82
###begin p 83
Gonadal tissue not found at laparoscopy at age 31 years.
###end p 83
###begin p 84
SLD, sex-limited dominant; +, present; -, absent; (+), remnant present.
###end p 84

